AU2001264824A1 - Vaccine and gene therapy vector and methods of use thereof - Google Patents

Vaccine and gene therapy vector and methods of use thereof

Info

Publication number
AU2001264824A1
AU2001264824A1 AU2001264824A AU6482401A AU2001264824A1 AU 2001264824 A1 AU2001264824 A1 AU 2001264824A1 AU 2001264824 A AU2001264824 A AU 2001264824A AU 6482401 A AU6482401 A AU 6482401A AU 2001264824 A1 AU2001264824 A1 AU 2001264824A1
Authority
AU
Australia
Prior art keywords
vaccine
methods
gene therapy
therapy vector
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001264824A
Inventor
Allen Portner
Toru Takimoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
St Jude Childrens Research Hospital
Original Assignee
St Jude Childrens Research Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St Jude Childrens Research Hospital filed Critical St Jude Childrens Research Hospital
Publication of AU2001264824A1 publication Critical patent/AU2001264824A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18841—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18843—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
AU2001264824A 2000-06-01 2001-05-22 Vaccine and gene therapy vector and methods of use thereof Abandoned AU2001264824A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20870100P 2000-06-01 2000-06-01
US60/208,701 2000-06-01
PCT/US2001/016610 WO2001092548A2 (en) 2000-06-01 2001-05-22 Vaccine and gene therapy vector and methods of use thereof

Publications (1)

Publication Number Publication Date
AU2001264824A1 true AU2001264824A1 (en) 2001-12-11

Family

ID=22775651

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001264824A Abandoned AU2001264824A1 (en) 2000-06-01 2001-05-22 Vaccine and gene therapy vector and methods of use thereof

Country Status (2)

Country Link
AU (1) AU2001264824A1 (en)
WO (1) WO2001092548A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1629004T1 (en) 2003-06-05 2008-12-31 Wyeth Corp Immunogenic compositions comprising venezuelan equine encephalitis virus replicon vectors and paramyxovirus protein antigens
AU2009236585B2 (en) * 2008-04-18 2013-03-07 Vaxinnate Corporation Deletion mutants of flagellin and methods of use
WO2012148708A1 (en) 2011-04-28 2012-11-01 St. Jude Children's Research Hospital Modified sendai virus vaccine and imaging vector
EP2813574B1 (en) * 2013-06-10 2019-02-20 RSV Genius GmbH Semi-live respiratory syncytial virus vaccine
EP3681523A4 (en) * 2017-09-15 2021-12-29 The Ohio State Innovation Foundation Vaccines and methods of making and using vaccines for prevention of respiratory syncytial virus (rsv) infections
JP2024511644A (en) * 2021-04-01 2024-03-14 ヤンセン ファッシンズ アンド プリベンション ベーフェー Stabilized prefusion PIV3 F protein

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1143892C (en) * 1995-11-01 2004-03-31 株式会社载体研究所 Recombinant sendal virus

Also Published As

Publication number Publication date
WO2001092548A3 (en) 2003-03-27
WO2001092548A2 (en) 2001-12-06

Similar Documents

Publication Publication Date Title
AU1194802A (en) DNA expression vectors and methods of use
EP1406653A4 (en) T cell regulatory genes and methods of use thereof
AU2003235707A1 (en) Immunogenic preparations and vaccines on the basis of mrna
AU2002314466A1 (en) Withasol and methods of use
AU2001241918A1 (en) Methods of enhancing activity of vaccines and vaccine compositions
AU2002335085A1 (en) Angiopoietins and methods of use thereof
AU2001245987A1 (en) Compositions and methods for gene therapy
AU2002326751A1 (en) Immunoglobulin e vaccines and methods of use thereof
AU2002246808A1 (en) Human nucleic acids and polypeptides and methods of use thereof
IL144845A0 (en) Vaccines and gene therapy compositions and methods of making and using the same
AU2002365202A1 (en) Synthetic genes for malarial proteins and methods of use
AU2001264824A1 (en) Vaccine and gene therapy vector and methods of use thereof
AU2001255521A1 (en) Biphasic reaction vessel and methods of use
AU2002347464A1 (en) Anti-arthropod vector vaccines methods of selecting and uses thereof
AU2002363938A1 (en) Methods and use of motoneuronotropic factors
AU2001251138A1 (en) Compositions and methods for tissue specific gene regulation therapy
AU2001261496A1 (en) Luxo-sigma54 interactions and methods of use
AU2001249692A1 (en) Phospholipid scramblases and methods of use thereof
GB0127657D0 (en) Virulence genes and proteins and their use
AU2001296448A1 (en) Tumor marker and methods of use
AU4801000A (en) Nucleic acid vaccines against rickettsial diseases and methods of use
AU2001284380A1 (en) Therapeutic and cosmetic uses of heparanases
GB0013108D0 (en) Extended duration of airway gene therapy
AUPQ760400A0 (en) Herbical formulations and methods of use thereof
AU2002323598A1 (en) Measles vaccine vectors and methods of use